Rajith K. R. Rajoli

<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Carolina Q. Sacramento, Natalia Fintelman‐Rodrigues, Jairo R. Temerozo et al. · Journal of Antimicrobial Chemotherapy · 2021 · 98 citations · Full text

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV

Rajith K. R. Rajoli, David Back, Steve P. Rannard et al. · Clinical Pharmacokinetics · 2014 · 93 citations · Full text

Cell-based Drug Delivery, Nanomedicine, Intramuscular Long-acting Nanoformulations +12

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Rajith K. R. Rajoli, Henry Pertinez, Usman Arshad et al. · British Journal of Clinical Pharmacology · 2020 · 56 citations · Full text

Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK

Rajith K. R. Rajoli, Charles Flexner, Justin Chiong et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2019 · 51 citations · Full text

Engineering, Long-acting Antiretrovirals, Microfabrication +6

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

Rajith K. R. Rajoli, Paul Curley, Justin Chiong et al. · The Journal of Infectious Diseases · 2018 · 47 citations · Full text